Women had about a twofold higher risk than men of developing dermatologic adverse events while taking immune checkpoint inhibitors for metastatic melanoma in a review of 235 patients at Dana Farber Cancer Center, Boston, Massachusetts. Overall, 62.4% of the 93 women in the review and 48.6% of the 142 men experienced confirmed skin reactions, for